Glumetza (extended-release metformin) by Depomed and Biovail Corp. received approval from the FDA in June for the treatment of type 2 diabetes, according to a company news release. Glumetza is a once-daily extended-release formulation of metformin hydrochloride.
Glumetza may offer potential advantages such as less-frequent dosing and proven effectiveness in combination with other diabetes drugs, according to the release. Glumetza also offers excellent tolerability so that health care providers can more quickly administer a dose high enough to provide glycemic control without significantly increasing the incidence of side effects such as diarrhea and nausea, according to the release.
Patients with kidney problems, metabolic acidosis or heart failure that is treated with medicine should not take Glumetza. Because Glumetza can cause lactic acidosis, patients should stop taking Glumetza and call their health care providers immediately if they feel very weak or tired, or have unusual muscle pain, trouble breathing, stomach pain with nausea and vomiting, or diarrhea. Other signs of lactic acidosis are feeling cold, especially in the arms or legs, dizziness and lightheadedness.
No comments:
Post a Comment